GlassScriptPhysician profile
Gregory S Backofen
NPI 1619231966
$568.09
in general payments reported to CMS, 2019-2025
11 companies · $148 in 2025
The $148 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.01 · 2020: $31.39 · 2021: $76.44 · 2023: $110 · 2024: $173 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $431.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $179.05 | 2021-2025 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $142.10 | 2023-2024 | Rexulti |
| Lilly USA, LLC | $83.97 | 2020-2024 | Mounjaro, Zepbound |
| Tactile Systems Technology INC | $30.65 | 2024 | Flexitouch Plus, Entre Plus |
| Pfizer INC. | $29.69 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.32 | 2025 | Xifaxan |
| Paratek Pharmaceuticals, INC. | $20.33 | 2025 | Nuzyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.82 | 2025 | Caplyta |
| Biogen, INC. | $15.22 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.18 | 2023 | Quviviq |
| Merck Sharp & Dohme LLC | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Backofen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.